Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people taking Wegovy start to see measurable weight loss within the first four to eight weeks, though the pace varies considerably from person to person. In the pivotal STEP 1 clinical trial, participants lost an average of around 15% of their body weight over 68 weeks at the 2.4 mg maintenance dose. That figure is an average across thousands of adults — your own rate will depend on your starting weight, the dose you're on, how your body responds to semaglutide, and the lifestyle changes you make alongside treatment. Wegovy is a prescription-only medicine, so a prescriber will assess whether it's clinically suitable for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. By the end, the semaglutide 2.4 mg group had lost an average of roughly 15% of their starting body weight compared with around 2.4% in the placebo group. For someone starting at 100 kg, that translates to approximately 15 kg — though plenty of participants lost more, and some lost less.
Weight loss was not linear throughout the trial. The steepest drops tended to come in weeks four to twenty-four, once the maintenance dose was reached and appetite suppression was at its strongest. After that, loss typically slowed and plateaued, which is normal biology rather than the treatment failing. If you want a granular breakdown of the week-by-week picture, the rate of Wegovy weight loss page covers the trajectory in more detail.
One misconception worth letting go gently: many people assume the first pen delivers dramatic results. It doesn't, and it isn't designed to. The 0.25 mg starting dose exists to help your body adjust to the medicine, not to drive significant weight loss. The therapeutic effect builds as the dose increases over the following months.
Wegovy is started at 0.25 mg once weekly and the dose is stepped up roughly every four weeks, through 0.5 mg, 1.0 mg and 1.7 mg, to the 2.4 mg maintenance dose, a process that takes around sixteen to twenty weeks in total. For the highest dose option now available, the MHRA approved a 7.2 mg single-dose pen in April 2026, which trials suggest could push average losses to around 20.7% over 72 weeks, though your prescriber decides whether that dose is appropriate for you.
This step-up structure means the speed at which weight comes off in month one looks very different from month five. Expecting rapid loss early is reasonable, but the bigger drops tend to arrive once your body is running on the full therapeutic dose. If you're curious about how fast you lose weight on Wegovy at each stage of the dose increase, that page breaks down what to expect month by month. People who understand this tend to stick with treatment through the slower early weeks, which is where persistence pays off.
The question of how long Wegovy takes to work is closely tied to where you are in the titration curve, and it's worth reading if you're trying to set realistic expectations before starting.
Two people on identical doses can lose weight at quite different speeds. Starting body weight matters: someone with a higher BMI often sees larger absolute losses early on, even if the percentage change is similar. Metabolic rate, age, hormonal factors, and how well the medicine suppresses appetite individually all play a role. So does what you eat and how active you are, the trial participants followed a reduced-calorie diet alongside treatment, and that lifestyle component is part of how the medicine is licensed to be used, per NICE's guidance on semaglutide (TA875).
Sleep, stress, and medications you're already taking can also influence the rate. There's no reliable formula that predicts your personal trajectory from a standing start. What the trial data gives you is a realistic range; what your prescriber gives you is an assessment of where in that range you might land.
If you're trying to work out how your timeline compares to others, how long it typically takes to lose weight on Wegovy sets out the fuller picture. Reading through Wegovy stories from people who have been through the process before and after their treatment can also help you build a grounded sense of what real-world results look like. And if you're weighing up Wegovy against other treatments, our weight-loss treatment overview covers the options side by side. Cost is a practical factor too, the Wegovy price comparison page explains what legitimate private treatment involves in the UK.
If this is the right medicine for you is a clinical question. Speak to our prescribers, a real clinician reviews your consultation the same day, and treatment is dispatched the next working day once approved. Start your free consultation to find out whether you're eligible.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.